William Blair & Company
IBRX icon

William Blair & Company’s ImmunityBio IBRX Stock Holding History

William Blair & Company’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.12M Buy
241,956
+15
+0% +$114 0.01% 743
2026
Q1 		$1.86M Buy
241,941
+1,727
+0.7% +$11.8K 0.01% 752
2025
Q4 		$476K Hold
240,214
– – ﹤0.01% 1161
2025
Q3 		$591K Buy
240,214
+400
+0.2% +$1.03K ﹤0.01% 1064
2025
Q2 		$633K Buy
239,814
+6,314
+3% +$17K ﹤0.01% 1021
2025
Q1 		$703K Hold
233,500
– – ﹤0.01% 981
2024
Q4 		$598K Buy
233,500
+26,700
+13% +$111K ﹤0.01% 1043
2024
Q3 		$769K Hold
206,800
– – ﹤0.01% 983
2024
Q2 		$1.31M Sell
206,800
-106,742
-34% -$704K ﹤0.01% 801
2024
Q1 		$1.68M Buy
313,542
+161,530
+106% +$731K 0.01% 722
2023
Q4 		$763K Sell
152,012
-10,450
-6% -$32.8K ﹤0.01% 946
2023
Q3 		$275K Buy
162,462
+108,431
+201% +$218K ﹤0.01% 1271
2023
Q2 		$150K Buy
54,031
+1,000
+2% +$2.83K ﹤0.01% 1457
2023
Q1 		$96.5K Hold
53,031
– – ﹤0.01% 1507
2022
Q4 		$269K Sell
53,031
-500
-0.9% -$2.75K ﹤0.01% 1272
2022
Q3 		$266K Hold
53,531
– – ﹤0.01% 1277
2022
Q2 		$199K Buy
53,531
+20,531
+62% +$82.5K ﹤0.01% 1422
2022
Q1 		$185K Hold
33,000
– – ﹤0.01% 1538
2021
Q4 		$201K Hold
33,000
– – ﹤0.01% 1572
2021
Q3 		$321K Buy
33,000
+8,000
+32% +$88K ﹤0.01% 1321
2021
Q2 		$357K Buy
25,000
+8,000
+47% +$132K ﹤0.01% 1280
2021
Q1 		$404K Buy
+17,000
New +$441K ﹤0.01% 1217

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

William Blair & Company's IBRX Position: Q2 2026 in Review

William Blair & Company increased its ImmunityBio (IBRX) stake by 0.01% in Q2 2026, buying an estimated $114 and bringing the position to 241,956 shares worth $2.12M. The position accounts for 0.01% of the portfolio, ranked #743.

William Blair & Company first reported a position in IBRX in Q1 2021 and has held it in 22 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • William Blair & Company held 241,956 shares of ImmunityBio worth $2.12M as of Q2 2026.
  • William Blair & Company bought 15 ImmunityBio shares in Q2 2026, an estimated $114.
  • ImmunityBio made up 0.01% of William Blair & Company's portfolio in Q2 2026, its #743 holding.
  • William Blair & Company first reported a position in ImmunityBio in Q1 2021 and has held it in 22 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.